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It is an honor for me to present to you today.
First, let me set the record straight. My priorities in
life have been very simple. They have been God,
family, country, the New York Yankees, and the
University of Notre Dame. Nothing else in my life
has mattered. Certainly, my friends are in the cate-
gory of family. Notice that medicine is not on this list,
nor will it ever be on this list. However, a subgroup of
individuals in medicine is part of my family, and I will
talk about them at the end of this presentation.
It has been an honor and privilege to be your
President over the past year. It is traditional to start
presidential addresses by thanking individuals, and,
as I have stated before, I have never been traditional,
but I am breaking my rule this morning. I would not
be standing before you if it wasn’t for several indi-
viduals that I need to thank. First and foremost, I
would like to thank my family. I’d like to thank my
wife, Cathy, and my two daughters for tolerating a
lot of my antics over the years. They indeed are the
love of my life, although at times I know it didn’t
seem that way.
My academic career would not be what it is if it
wasn’t for my 23 years at the Roswell Park Cancer
Institute. There are many individuals to thank, but I
would like to especially mention four. Arnold
Mittelman who was my mentor for 28 years and my
father away from home. I miss him. Harold Dou-
glass, former Chief of the GI Surgical Service at
Roswell Park, and Hector Nava, Associate Chief of
GI and probably one of the best endoscopists in the
country. I have one story that I would like to share
with you concerning Dr. Harold Douglass. Soon
after I was appointed Chief of Surgical Oncology at
Roswell Park, an anesthesiologist had been diag-
nosed with liver metastases from colon cancer. The
anesthesiologist asked me, Harold Douglass, and
Hector Nava to scrub on the case. Keep in mind
that both Harold Douglass and Hector Nava were
teachers of mine during my fellowship. Of course,
the morning of the surgery, I prepped and draped
the patient and then took my position as the second
assistant at the table. The scrub nurse passed the
scalpel to Harold Douglass, Chief of GI. Without
saying a word, he pointed to me. I assumed my
position as surgeon at the OR table. As Dr. Nava
was moving toward the second assistant position,
Harold Douglass told him to stay at the ﬁrst posi-
tion, and then Harold Douglass himself moved to
the second assistant position. This case was one of
the most satisfying in my career, and it demon-
strated to me the ultimate mentorship which was
exempliﬁed by Harold Douglass.
The fourth individual is Constantine Karakousis,
surgeon and poet, an individual who despite a tre-
mendous volume of surgical experience with mela-
noma and sarcoma, would always pull out an
anatomy book in the locker room prior to each sur-
gical procedure to review the anatomic relationships
that he and the surgical team would face. It was an
example set for everyone from the level of medical
student to attending staﬀ, and I thank him for that
and the many other experiences that we shared.
Last year, Dr. Pollock started his Presidential
Address by relating to you the struggles that he had
with a topic for presentation. I had the same. I went
through a list of topics which included the treatment
of colorectal cancer and clinical trials in view of my
experience in the NCI Cooperative Groups. Frankly,
those were boring to me. Let’s face it, we have gone
from a median survival of 9 months to 20 months for
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2069patients with stage IV unresectable colorectal cancer
with the new systemic agents so I am happy for pa-
tients. I am not happy for us as clinicians and
researchers because it has taken us 40 years, with the
same drug, and we are still only palliating and not
curing patients. Lastly, there was the topic of vision
for the Society. As far seeing a vision, my track re-
cord consists of predicting the Yankees would win the
World Series last year and the Irish would have a
winning football season. You don’t want to hear my
vision for the Society.
As I was going through a list of topics, I noticed
many of the diplomas and Society memberships that
were hanging in my study. An important question
came to mind that I had never asked myself before,
and that was, ‘‘What contributions have I made to
society outside of the ﬁeld of medicine?’’ Think about
that question yourself. Don’t get me wrong, caring
for patients is one, if not the best and most satisfying
profession in the world. But we all do that. It re-
minded me of what my wife has asked me numerous
times throughout my career—’’Do you want your
epitaph to say here lies a good surgical oncologist or
here lies a good husband and father?’’ Now there are
numerous examples of contributions to society that
I’m sure many of you have contributed outside the
ﬁeld of medicine, but I would like to share one.
Lieutenant Colonel Alan Beitler, Lieutenant Col-
onel Jim North, and Lieutenant Colonel Brad Wad-
dle, please stand. Like other individuals who are in
the armed forces and are sitting in this audience, these
three individuals have put their lives on the line in
order for us to sit here over the next three days at this
meeting without the worry of a suicide bomber hit-
ting this hotel. These gentlemen have had numerous
publications and presentations, but to me, this con-
tribution of protecting our country is their greatest.
Gentlemen, thank you for ﬁghting for our freedom,
please sit down.
As a side note, I showed a gift from these three
gentlemantomyDadwhowasaWorldWarIIveteran
and one of the most patriotic individuals I have
known. This is an individual who made me salute the
American ﬂag on TV when the National Anthem
wouldplaypriortotheYankeegames.WhenIshowed
him this gift which has sat on our living room coﬀee
table since 2000, tears welled to his eyes. My dad was
born and raised in New York City and loved the City
and always thought of it as the center of the universe.
He died August 5, 2001, four days after I started my
job in Delaware. This was slightly before 9/11.
So what topic did I decide upon, because you can’t
tell by the title of my talk, which is from the piano
man from Hicksville, Long Island? Although it does
signify ‘‘attitude.’’ My presentation centers on the
core of these individuals (Fig. 1). This Presidential
presentation is not about me, it’s about these indi-
viduals and what has been accomplished in a com-
munity-based teaching hospital/cancer center in a
state that had until recently the highest cancer inci-
dence and mortality in the United States. I don’t
know why it took us so long to recognize the
importance of the community surgeon as being a
member of our Society. I congratulate Dr. Pollock
and the Executive Council and the overwhelming
majority of the membership for realizing that there
are community surgeons performing outstanding
cancer care in this country that should be given the
privilege of joining our Society.
Importantly, as the Coalition of Cooperative
Groups under Bob Comis, PI of ECOG, has shown,
the majority of accrual to clinical trials comes from
community-based practices. The community physi-
cians are the key to NCI trial accrual. Those quality
physicians, many of whom are surgeons, need to
become members of SSO.
I would also recommend to Drs. Balch and Roh
that they add an editorial section to the Annals of
Surgical Oncology entitled ‘‘Community Cancer
Center Outcomes’’ or at least add community sur-
geons who are members of our Society to be on that
editorial board or minimally have Rick Green the
section editor of Health Care Policy and Outcomes
add community surgeons to his Editorial Section.
They will do an outstanding job of manuscript re-
view, and perhaps it will stimulate community cancer
centers to publish their outcomes.
So I’d like to spend a little bit of time in demon-
strating to you what a core of high-quality individu-
als can accomplish in a short period of time in a
community-based teaching hospital/cancer center.
Our physicians and others have been committed to a
statewide program of cancer care. Despite busy
practices, they indeed have found the time to build
programs, buy into a vision, receive peer review
funding, participate in translational cancer research,
and publish in quality journals resulting in quality
cancer care in Delaware.
John Wooden, the Wizard of Westwood, an icon
among basketball coaches, described a leader as one
who has to accomplish the diﬃcult task of getting
those on the team to believe that ‘‘we’’ supersedes
‘‘me.’’ Frankly, I prefer my own deﬁnition of a lea-
der: ‘‘To be successful as a leader, surround yourself
with individuals who are smarter than you, but just
don’t let them know that.’’ Walt Disney was a lousy
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he was convinced to succeed he needed to surround
himself with great artists and hire his brother to
handle the ﬁnances. With these two moves he was free
to do what he did best: use his imagination. Leaders
also need to think outside the box. It is important to
leave the established road map behind to explore new
territories.
The Helen F. Graham Cancer Center is just one
part of Christiana Care, which is a matrix system that
includes the only Level I trauma between Philadelphia
and Baltimore. We see over 3000 new cancer cases per
year, and it is a very busy surgical campus with over
40,000 surgical procedures per year. Delaware does
not have a physical presence of a medical school; the
chartered medical school is Jeﬀerson Medical College.
Aside from the Jeﬀerson medical students who rotate
through the campus, Christiana has its own residency
and fellowship programs, including an excellent gen-
eral surgery residency program represented by Dr.
Michael Rhodes, Chief of the Department of Surgery,
who is in this audience today. Clinical research
abounds not only in cancer, but also in other areas. So
the visionfor this Cancer Program since 2002 has been
to raise the standard of oncology care in the state.
This has occurred through four major clinical pro-
grams: educational programs such as DOCS or the
Delaware Oncology Conferences, which is a statewide
program of videoconferencing—the DOCS Program
is being presented by Dr. Diana Dickson-Witmer at
our meeting this week; increasing accrual to NCI
clinical trials and early detection and prevention
programs, especially in a state that used to be number
one in cancer incidence and mortality; and lastly, an
integrated statewide health care system. The strategic
plan (Fig. 2) has been built around developing and
implementing the multidisciplinary care of the cancer
patient in the state. This started at the local level at the
Helen F. Graham Cancer Center, and the plan has
been and continues to expand across the state with
resources that include the spectrum of peer-reviewed
grants and state government funding. We are a small
state, which poses major challenges, but also oppor-
tunities. The state has seven hospitals that are just
about evenly distributed throughout the three coun-
ties in the state. At the present time, four of the seven
hospitals are involved in NCI clinical trials and part of
the state cancer control plan for 2007–2010 is to have
FIG. 1. Individuals responsible for contributing to cancer program development at the Helen F. Graham Cancer Center and throughout the
state of Delaware.
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accrual. There are interesting dynamics in the state.
North of the Delaware Chesapeake Canal is what I
like to call ‘‘corporate America,’’ and south of the
canal are beautiful beaches and farmlands and a large
population of medically underserved. Collaborative
efforts with Beebe Hospital and Dr. Jim Spellman,
also a member of our society, in the most southern
county has allowed us to bridge the gap of cancer care
in the state.
The strategic plan and vision has been built around
developing an infrastructure of high-quality physi-
cians with support staﬀ and the multidisciplinary
team approach to cancer care. These two components
have allowed academic productivity, a strong NCI
clinical trials and pharmaceutical trials program,
early detection and prevention program develop-
ment, and, believe it or not, translational cancer
research with the goal of being recognized by the
National Cancer Institute. So we were at the right
place at the right time, and in May of 2007 we were
selected by the NCI as one of only 14 community
cancer centers in the U.S. to participate in the new
NCI Community Cancer Center Program, or
NCCCP. Now, this NCI program was not only put
together to increase access to NCI-sponsored clinical
trials but with an emphasis on minority recruitment,
but also reducing cancer health care disparities, col-
lecting materials for translational cancer research,
utilizing the NCI Cancer Biomedical Informatics
Grid, ca-BIG, to develop a national database of
electronic medical records, and quality-of-life best
practice outcomes and survivorship programs
starting with colorectal and breast carcinoma. All
of this to bring more Americans into a system of
high-quality cancer care. What’s wrong with that?
Nothing! Some of the reasons for developing the
NCCCP program included the fact that 85% of
cancer patients in the United States are diagnosed at
hospitals in their communities. The other 15% are
diagnosed at NCI-designated cancer centers, which
are 63 academic institutions mainly in urban areas.
Many patients are not treated at major cancer centers
because of distance from home, personal, or eco-
nomic reasons.
With that backdrop, I’d like to brieﬂy discuss four
programs, which have been successful because of the
high-quality physicians that I showed you just sev-
eral minutes ago. These programs deal with our
statewide high-risk family cancer registry, our NCI
clinical trials CCOP program, our multidisciplinary
disease site centers, and translational cancer re-
search. Prior to August 2002, there was not one full-
time adult genetic counselor in the state of Delaware.
Following recruitment, we now have three full-time
adult genetic counselors at the Graham Cancer
Center. Over the last 5 years, this high-risk family
cancer registry named after the governor of the state
has collected 900 families with over 30,000 individ-
uals. This is a genetic counseling and gene-testing
program that has spanned across the state. It in-
volves a collaborative eﬀort between surgeons, fam-
ily practice physicians, and medical oncologists. One
of the reasons it has been eﬀective is that on a weekly
basis, the genetic counselors travel to the most
southern part of the state to see patients so that they
don’t have to travel to the Helen F. Graham Cancer
Center. The high-risk family cancer registry has re-
quired a tremendous educational eﬀort. As you can
see (Fig. 3) in 2002, approximately 50% of individ-
uals who were offered genetic testing actually
underwent gene testing. However, in 2007, 92% of
individuals offered genetic testing actually had the
FIG. 2. A strategic plan for the multidisciplinary care of the cancer
patient in Delaware.
FIG. 3. Percent of individuals undergoing gene testing following
genetic counseling from 2002–2007. The national average is 70%.
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Well, what has been the impact of genetic testing on
individuals where gene alterations have been dis-
covered? Ninety to 95% have had an impact on their
health care management either with prophylactic
surgery, increased cancer surveillance, participation
in NCI clinical trials, or chemoprevention. Medical
oncologists often spend a great deal of effort trying
to squeeze in an extra few months of a cancer pa-
tient’s life, but no matter how effective our treat-
ments become, they will never be as effective as
avoidance of the cancer in the ﬁrst place. The
greatest opportunity to save lives lies in the appro-
priate counseling and testing of at-risk family mem-
bers of patients with genetic mutations.
Now I would like to turn our attention to the
second program, which was the development of the
multidisciplinary disease site centers. These were
established in 2002. We started with only three cen-
ters: thoracic, head and neck, and a general oncology
center to handle all other cancers. However, through
the hard work of our physicians and support per-
sonnel, we now have 16 multidisciplinary disease site
centers (Fig. 4). In each of these centers, a medical
oncologist, surgeon, and radiation oncologist are
physically present to discuss patient treatment and
diagnostic procedures. However, aside from the three
major disciplines, these disease site centers also have
participation by support staff such as nurse naviga-
tors, clinical trials nurses, genetic counselors, nutri-
tionists, psychologists, and subspecialists such as
interventional radiologists and physiatrists. These
multidisciplinary disease site centers have decreased
the fragmentation of cancer care which existed prior
to their establishment. Patients no longer have to wait
several weeks or months to see a medical, surgical,
and radiation oncologist. The treatment plan can be
established in one visit with a centralized follow-up
plan and measures of outcomes (Fig. 5).
Believe me, starting these multidisciplinary centers
was no easy task. The key was identifying high-
quality physicians, obtaining their support as leaders,
developing a formal participation agreement between
the hospital and physicians, and ﬁnally, a leadership
committee to design and review performance criteria
(Fig. 6).
Figure 7 demonstrates the 11 performance criteria
for physicians who want to participate in the multi-
disciplinary centers. They include criteria such as a
track record of placing patients on NCI clinical trials
FIG. 4. The 16 multidisciplinary disease site centers at the Helen F. Graham Cancer Center where a medical oncologist, surgeon, and
radiation oncologist are physically present along with all support services, such as genetic counselors, nutritionists, psychologists, and
subspecialists, such as interventional radiologists and physiatrists.
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tumor conferences in the cancer center, and partici-
pating in quality-of-care outcome programs. So one
example of the success of these MDCs is demon-
strated by our sarcoma multidisciplinary center
where after recruiting high-quality physicians on
campus and from outside recruitment, patients think
twice before leaving the state for their sarcoma care.
These multidisciplinary disease site centers have al-
lowed immediate access for patients to clinical trials,
especially in the adjuvant and prevention trial envi-
ronment. They have also allowed access to genetic
counselors for detailed family history and gene test-
ing followed by recommendations for prophylactic
surgery, chemoprevention, or increased surveillance
in individuals who are part of the high-risk family
cancer registry.
The next program that I would like to brieﬂy dis-
cuss is the NCI Delaware Christiana CCOP. This is
under the direction of Dr. Stephen Grubbs, PI of the
CCOP, a medical oncologist who is also in the
audience today. I have been asked numerous times
how we were able to get our patient accrual rate to
NCI clinical trials above 20%. Drs. Grubbs, Gru-
senmeyer, and I know it’s a simple formula for suc-
cess. Resources · personnel = high accrual. Of
course, the hard part and caveat is that resources
means one thing: money. And, of course, personnel
equals high-quality physicians and clinical research
associates who are willing to commit time in an efﬁ-
ciently run system. I can’t emphasize enough that the
system has to run eﬃciently. We have been very
fortunate because of our leadership and hardworking
nurses and physicians to have an increase in our
CCOP funding since 2002. Our NCI accrual to clin-
ical trials is just over 20%; however, when you add
our other clinical trial programs, (pharmaceutical,
translational research), it is 30% (Fig. 8). However,
our goal for the Helen F. Graham Cancer Center in
the next 3 years is to reach the 30% accrual rate for
NCI trials alone. Here’s one way we plan to do it. In
January 2008, we established criteria for becoming an
NCI Clinical Trials Investigator. Why not?—you
must earn that status and give it credibility. The cri-
teria are a minimum of four patients accrued to NCI
trials in 1 year, attend one NCI Cooperative or
CCOP research base meeting every other year, and
have your medical records undergo an internal and
external audit on a regular schedule in preparation
for NCI Cooperative group audits. Failure to meet
these criteria results in your investigator status being
revoked. If you want to be reinstated you need to
wait 1 year, attend an NCI Group meeting, and pay
$500.
1
I mentioned at the beginning of this talk that
translational cancer research was a goal of our cancer
center. How could this be possible in a community
cancer center? Well, I hope I’ve already demonstrated
to you the strong infrastructure that we have with a
strong multidisciplinary approach to cancer care.
When you add on to that a major university, such as
the University of Delaware (UD), 6 miles from the
Helen F. Graham Cancer Center, and other colleges
in the state inclusive of a strong department of Bio-
logic Sciences at UD, it seemed to me that a second
strong infrastructure could evolve for translational
cancer research. Hence, a $16 million NIH Idea
Network of Biomedical Research Excellence Award
(INBRE Grant) allowed the University of Delaware
and Helen F. Graham Cancer Center to establish in
February 2006 a Center for Translational Cancer
Research. These NIH grants allowed us to establish a
FIG. 5. Multidisciplinary disease site center outcomes demon-
strating some of the beneﬁts of this type of cancer care.
FIG. 6. The elements necessary to develop a multidisciplinary
disease site clinic/center.
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over 200 specimens inclusive of a database for patient
demographics and treatment status. This obviously
serves as a strong resource for translational research.
Figure 9 is a list of many of the translational cancer
research projects that are now ongoing. The indi-
viduals underlined are clinicians at the Helen F.
Graham Cancer Center who are collaborating with
FIG. 7. The 11 performance criteria needed for physicians who want to participate in the Helen F. Graham Cancer Center multidisciplinary
disease site centers.
FIG. 8. The National Cancer Institute accrual to clinical trials at the Helen F. Graham Cancer Center at Christiana Care is just over 20%. It
is 30% when the NCI trials are added to other clinical trials programs, such as translational cancer research and pharmaceutical trials.
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pects of cancer research. The Center for Translational
Cancer Research has also had monetary support
from state government. Again, in a small state, pro-
grams can be successful in an extremely short period
of time.
So these programs and others have allowed the
state of Delaware to make tremendous progress over
the last 6 years in cancer incidence and mortality. In
2006, the Centers for Disease Control (CDC) re-
ported that cancer deaths decreased in 16 states. They
declined by more than 12 deaths per 100,000 in
Delaware. As a matter of fact as you all sit here in
this audience today, Delaware has the most rapid
decline in cancer mortality in the United States.
Twice as fast as the United States rate. For the ﬁrst
time since the American Cancer Society has kept
statistics on cancer incidence and death rates, Dela-
ware is no longer in the top 10 in both incidence and
deaths. Keep in mind that we used to be number 1 on
both of these lists. This is not one top 10 list you want
to be on.
Of course, state government has played a major
role in helping to decrease the cancer incidence and
mortality in the state. In November of 2002, the state
passed the strictest clean indoor air act in this coun-
try. It has a statewide program to screen all Dela-
wareans over the age of 50 with colonoscopy. Early
results show a narrowing in disparity of African
Americans for colorectal cancer screening (Fig. 10).
Unprecedented in this country, the Delaware Cancer
Treatment Program will pay for 2 years of cancer
care in an uninsured family of four where their family
income is up to $120,000 a year. Aside from the
Screening for Life Programs funded by the CDC,
there is a major HPV vaccine educational program
for cervical cancer through the immunization regis-
try. All of these programs are the reason Lieutenant
Governor John Carney is receiving the James Ewing
Layman’s Award Saturday evening. However, in my
mind, these state programs would not be as successful
without the Helen F. Graham Cancer Center, which
serves as the focus for cancer program development
and especially leadership. I’m sure Lieutenant Gov-
ernor Carney would agree.
So in 2002, we started with 60,000 square feet, and,
because of the success of our programs, by the spring
of 2009 we will have added an additional 124,000
square feet to our cancer center. This will allow us to
encompass all resources for cancer care under one
roof. Indeed, Delaware has come a long way, and, for
me personally, this whole process over the last 6 years
has truly been a labor of love.
As a semiﬁnal thought, and as my colleagues at
Christiana know, we constantly talk about trying to
change culture. In my mind, we need to begin to
change the culture in oncology. We need stronger
working relationships between oncologists in acade-
mia and those in community hospitals across this
country. I believe the new NCI initiative of the
community cancer programs (NCCCP) will help that
process. The SSO has and must continue to play a
FIG. 9. Translational cancer research projects ongoing between
clinicians at the Helen F. Graham Cancer Center in collaboration
with scientists at the University of Delaware. These research pro-
jects are part of the Center for Translational Cancer Research,
which is a joint venture between the Helen F. Graham Cancer
Center, the Department of Biologic Sciences at the University of
Delaware and the Nemours Research Institute at the A.I. DuPont
Children’s Hospital in Delaware.
FIG. 10. Government programs that have played a major role in
helping to decrease the cancer incidence and mortality in the state
of Delaware. In 2002, 47% of African Americans underwent
colonoscopy in the state, whereas in 2007, 69% underwent colon-
oscopy due to the statewide program to screen all Delawareans
over the age of 50 with colonoscopy.
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cancer care and the solutions to these problems will
be useful for investigators, practitioners, and patients
with their advocates.
Now let me turn to the last part of my talk: The
other members of my family. Individuals who I have
played a small role in their lives and surgical oncol-
ogy education. They all lived under three trainee
rules. First, don’t tell me how hard you have worked,
but rather what you have accomplished. Second, if it
was easy, anybody could do it. Third, repetition is the
key to education. There was a fourth rule that for-
tunately only a few have heard. That is ‘‘There is no
crying or whining in surgery, so suck it up.’’
I have spent more time with my fellows than with
my children. Why is that? It’s because of a commit-
ment I made to play a small role in the education of
these young men and women throughout their lives
not just in training, to watch them grow and mature
into talented physicians and adults. It all starts out
with many of us being mentors.
To me, mentorship has four phases. The ﬁrst is
serving as a teacher and guiding individuals to become
the best physician they can be. The second is being an
advisor for appropriate job positions and career aspi-
rations. The third is becoming a colleague where pa-
tientproblemsarediscussed,andthelastisbecominga
friend with discussions of family, life, good wine, beer,
andfood,butonlyaftertheirtrainingiscomplete.You
can’t be their friend during training. You are their
mentor. There is a big diﬀerence.
Frankly, trainees keep one young. They also keep
us on the cutting edge of knowledge and sometimes
life with the hope that one won’t fall oﬀ that edge.
They believe T.S. Elliot, who said ‘‘only those who
risk going too far can possibly ﬁnd out how far to go.’’
Yes, they work very hard, but they can also play
hard. They can develop long-lasting friendships even
if they didn’t graduate in the same class or as part
of a graduating class. They are indeed remarkable
young men and women.
However, when all is said and done, they do be-
come family. In the end, the bottom line is that all of
the hard work, all of the late nights, all of the bad-
gering by their mentor is done for the next generation
of young men and women. They do indeed under-
stand that it isn’t how hard you work in life, but what
you have accomplished. It has been my honor to
serve them, to play a small part in their lives, and to
be proud of what they have accomplished (Fig. 11).
As a ﬁnal thought, my advice through all of this for
young investigators in the audience is to dream.
Dream about what your careers can be, dream about
what your family life can be because if you are lucky
like me, many of those dreams will become a reality.
Electric Light Orchestra said it the best: ‘‘When you
get so down that you can’t get up, when you want so
much but you’re all out of luck, when you’re so
downhearted and misunderstood, just hold on tight
to your dreams.’’
Thank you and just keep rockin’ on!!
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